High dose chemotherapy with carboplatin, VP 16 ± ifosfamide in germ cell tumors: the Italian experience

G. Rosti, L. Albertazzi, R. Salvioni, F. Valzania, M. A. Bassetto, G. Pizzocaro, M. Marango

Research output: Contribution to journalArticlepeer-review

Abstract

This schedule has shown an interesting activity with nearly 40% of the patients achieving CR. Moreover 4 patients experienced an inversion rate (CR with ABMT when they never achieved this status before). In terms of toxicity, this schedule seems feasible with 2/28 toxic deaths, which is in the lower part of the range of major solid tumors ABMT programs. But even if the rationale is proper, a better patients' selection is required. The CCR (Continuous Complete Remission) rate is overimposable to other main studies previously published, but all our CCR were obtained in responding patients (Sensitive Relapses or unresectable PR). We may suggest that earlier transplantation is advisable when less tumor bulk is present and less clonal heterogeneity. The exact maximum tolerated dose of Carboplatin/VP 16/ifosfamide programs has not yet been clearly pointed out. The lack of major life-threatening episodes and neuro/nephrotoxicity may allow us to explore higher Carboplatin doses. Anyway the ultimate answer to the utility of ABMT trials must come from a randomized study in responding patients.

Original languageEnglish
Pages (from-to)94
Number of pages1
JournalBone Marrow Transplantation
Volume7
Issue numberSUPPL. 2
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'High dose chemotherapy with carboplatin, VP 16 ± ifosfamide in germ cell tumors: the Italian experience'. Together they form a unique fingerprint.

Cite this